Clinical Trials at Mercy Hospital Oklahoma City
As of August 2026, 53 paid clinical trials are recruiting at Mercy Hospital Oklahoma City, located at 4300 W MEMORIAL RD, OKLAHOMA CITY, OK 73120-8304, phone (405) 755-1515 in Oklahoma City, Oklahoma. Active studies at this site cover conditions such as Endometrial Cancer, Ovarian Cancer and Acute Myeloid Leukemia. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
53 clinical trials at Mercy Hospital Oklahoma City
·Clear filters·Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Family Communications After Genetic Testing
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
Cost Communication and Financial Navigation in Cancer Patients (COSTCOM)
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer
Reaching Rural Cancer Survivors Who Smoke Using Text-Based Program
Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
Common conditions studied in Oklahoma City
- Endometrial Cancer (17 active studies)
- Ovarian Cancer (14 active studies)
- Acute Myeloid Leukemia (13 active studies)
- Malignant Solid Neoplasm (10 active studies)
- Breast Cancer (9 active studies)
- Major Depressive Disorder (9 active studies)
Leading research sponsors in Oklahoma City
- University of Oklahoma
- National Cancer Institute (NCI)
- Alliance for Clinical Trials in Oncology
- SWOG Cancer Research Network
- AstraZeneca
Frequently asked questions
How many paid clinical trials are currently recruiting in Oklahoma City?
There are approximately 595 recruiting clinical trials in Oklahoma City, Oklahoma listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Oklahoma City pay participants?
Most recruiting trials in Oklahoma City compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Oklahoma City?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Oklahoma City?
The most common conditions under active study in Oklahoma City include Endometrial Cancer (17), Ovarian Cancer (14), Acute Myeloid Leukemia (13), Malignant Solid Neoplasm (10), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Oklahoma City?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Oklahoma City on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Oklahoma City?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Oklahoma City?
Recruiting research sites in Oklahoma City include University of Oklahoma Health Sciences Center, Mercy Hospital Oklahoma City, University of Oklahoma, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Oklahoma City right now?
The largest active categories in Oklahoma City are Cancer & tumors (249), Cardiovascular (40), Diabetes & metabolic (27). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of Mercy Hospital Oklahoma City?
Mercy Hospital Oklahoma City is located at 4300 W MEMORIAL RD, OKLAHOMA CITY, OK 73120-8304. Use the Google Maps link in the intro above to get directions.
How do I contact Mercy Hospital Oklahoma City?
You can reach Mercy Hospital Oklahoma City by phone at (405) 755-1515. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.